Construction and characterisation of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits

Pozza, Tania Dalla; Yan, HR; Meek, DW; Ca, Guzmán; Walker, Mark J.

doi:10.1016/s0264-410x(97)80006-0

Cited by 13 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protection has been evaluated, however, against a recombinant S. typhimurium aroA mutant producing all five PTx subunits. Although this strain induced significant anti-PTx antibodies, it failed to protect mice from B. pertussis challenge (53).…”

Section: Pertussis Vaccination Via Mucosal Routesmentioning

confidence: 99%

The Role of Mucosal Immunity in Pertussis

Solans

Locht

2019

Front. Immunol.

View full text Add to dashboard Cite

Pertussis or whooping cough, mainly caused by Bordetella pertussis, is a severe respiratory disease that can affect all age groups but is most severe and can be life-threatening in young children. Vaccines against this disease are widely available since the 1950s. Despite high global vaccination coverage, the disease is not under control in any country, and its incidence is even increasing in several parts of the world. Epidemiological and experimental evidence has shown that the vaccines fail to prevent B. pertussis infection and transmission, although they are very effective in preventing disease. Given the high infection rate of B. pertussis, effective control of the disease likely requires prevention of infection and transmission in addition to protection against disease. With rare exceptions B. pertussis infections are restricted to the airways and do not usually disseminate beyond the respiratory epithelium. Therefore, protection at the level of the respiratory mucosa may be helpful for an improved control of pertussis. Yet, compared to systemic responses, mucosal immune responses have attracted relatively little attention in the context of pertussis vaccine development. In this review we summarize the available literature on the role of mucosal immunity in the prevention of B. pertussis infection. In contrast to vaccination, natural infection in humans and experimental infections in animals induce strong secretory IgA responses in the naso-pharynx and in the lungs. Several studies have shown that secretory IgA may be instrumental in the control of B. pertussis infection. Furthermore, studies in mouse models have revealed that B. pertussis infection, but not immunization with current acellular pertussis vaccines induces resident memory T cells, which may also contribute to protection against colonization by B. pertussis. As these resident memory T cells are long lived, vaccines that are able to induce them should provide long-lasting immunity. As of today, only one vaccine designed to induce potent mucosal immunity is in clinical development. This vaccine is a live attenuated B. pertussis strain delivered nasally in order to mimic the natural route of infection. Due to its ability to induce mucosal immunity it is expected that this approach will contribute to improved control of pertussis.

show abstract

Section: Pertussis Vaccination Via Mucosal Routesmentioning

confidence: 99%

The Role of Mucosal Immunity in Pertussis

Solans

Locht

2019

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Hoiseth and Stocker note that these factors are not found in mammalian hosts in sufficient amount; thus Salmonella aroA mutants cannot proliferate in mammalian hosts (Hoiseth and Stocker 1981). Harnessing this knowledge, various Salmonella enterica serovar Typhi (ST) or Typhimurium (STm) have been created, with mutations in aroA (Dalla Pozza et al 1998;Roberts et al 2000;Arnold et al 2004), aroC (Khan et al 2003;Capozzo et al 2004), aroD (Capozzo et al 2004;Sevil Domènech et al 2008), or aroAD (Strugnell et al 1992;Roberts et al 2000). Notably, the ST strain CVD908 which carries aroC and aroD mutations exhibits residual virulence in humans (Wang et al 2001), while other investigators have also targeted genes in nucleotide biosynthesis pathways for creating attenuated Salmonella.…”

Section: Attenuationmentioning

confidence: 99%

“…On the other hand, CTL response is generated against dengue virus (NS3) and HIV antigens (Karpenko et al 2004;Luria-Perez et al 2007). LABVs based on ST and STm elicit serum IgG, mucosal IgA, CD4 + T-cell, and CD8 + T-cell responses against a variety of bacterial pathogens including B. anthracis (Galen et al 2010), B. pertussis (Dalla Pozza et al 1998), E. coli (Ferreira Oliveira et al 2012), Helicobacter pylori (Angelakopoulos and Hohmann 2000), L. monocytogenes (Igwe et al 2002), Pseudomonas aeruginosa (Bumann et al 2010), Streptococcus pneumoniae (Shi et al 2010), and Yersinia pestis (Branger et al 2010). While antigen-specific Th1 responses are generated against some parasitic pathogens including Leishmania mexicana (González et al 1998), Schistosoma japonicum (Chen et al 2011), and Taenia solium (Ding et al 2013), mucosal IgG and IgA are generated against Giardia lamblia (Abdul-Wahid and Faubert 2007) and Cryptosporidium parvum (Benitez et al 2009) by ST-and STm-based LABVs carrying related antigens.…”

Section: Immune Mechanisms Of Vaccines Delivered By Live-attenuated Bmentioning

confidence: 99%

Live-Attenuated Bacterial Vectors for Delivery of Mucosal Vaccines, DNA Vaccines, and Cancer Immunotherapy

Kumar

2019

Environmental Chemistry for a Sustainable World

View full text Add to dashboard Cite

Vaccines save millions of lives each year from various life-threatening infectious diseases, and there are more than 20 vaccines currently licensed for human use worldwide. Moreover, in recent decades immunotherapy has become the mainstream therapy, which highlights the tremendous potential of immune response mediators, including vaccines for prevention and treatment of various forms of cancer. However, despite the tremendous advances in microbiology and immunology, there are several vaccine preventable diseases which still lack effective vaccines. Classically, weakened forms (attenuated) of pathogenic microbes were used as vaccines. Although the attenuated microbes induce effective immune response, a significant risk of reversion to pathogenic forms remains. While in the twenty-first

show abstract

Oral immunogenicity of tomato-derived sDPT polypeptide containing Corynebacterium diphtheriae, Bordetella pertussis and Clostridium tetani exotoxin epitopes

et al. 2010

View full text Add to dashboard Cite

DPT vaccine, designed to immunize against diphtheria, pertussis, and tetanus, has been shown to be effective in humans. Nevertheless, dissatisfaction with the whole-cell preparations is due to the reactogenicity, which has to lead to the development of new safer formulations. Previously, we described the expression in tomato of a plant-optimized synthetic gene encoding the recombinant polypeptide sDPT, containing mainly immunoprotective epitopes of the diphtheria, pertussis and tetanus exotoxins and two adjuvants. In this study, we examined whether the ingestion of tomato-derived sDPT protein induces specific antibodies in mice after three weekly doses scheme. A positive group immunized with DPT toxoids was included. Specific antibody levels were assessed in serum, gut and lung. Sera tested for IgG antibody response to pertussis, tetanus and diphtheria toxin showed responses to the foreign antigens; interestingly, the response to diphtheria epitope was similar to those observed in the positive group. We found higher IgG1 than IgG2a responses in serum. A modest IgG response was observed in the tracheopulmonary fluid. High response of IgA against tetanus toxin was evident in gut, which was statistically comparable to that obtained in the positive group. The levels of response in these groups were higher than those in mice that received wild-type tomato. These findings support the concept of using transgenic tomatoes expressing sDPT polypeptide as model for edible vaccine against diphtheria, pertussis, and tetanus.

show abstract

Construction and characterisation of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits

Cited by 13 publications

References 27 publications

The Role of Mucosal Immunity in Pertussis

The Role of Mucosal Immunity in Pertussis

Live-Attenuated Bacterial Vectors for Delivery of Mucosal Vaccines, DNA Vaccines, and Cancer Immunotherapy

Oral immunogenicity of tomato-derived sDPT polypeptide containing Corynebacterium diphtheriae, Bordetella pertussis and Clostridium tetani exotoxin epitopes

Contact Info

Product

Resources

About